MW-150 hydrochloride is used as a selective, orally active, brain-penetrant p38α MAPK inhibitor for the treatment of neuroinflammatory and neurodegenerative disorders; it improves cognitive performance in APP/PS1 transgenic mice and APPNLh/NLh×PSP264L/P264L knock-in mouse models of Alzheimer’s disease.